Guggenheim Forecasts Strong Price Appreciation for Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics (NASDAQ:MAZE) had its price objective hoisted by investment analysts at Guggenheim from $19.00 to $34.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 45.92% from the stock’s previous close.

Several other brokerages have also commented on MAZE. Wedbush began coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an “outperform” rating and a $17.00 target price on the stock. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. HC Wainwright upped their target price on Maze Therapeutics from $34.00 to $50.00 and gave the company a “buy” rating in a research report on Friday. Finally, BTIG Research upped their target price on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat.com, Maze Therapeutics currently has an average rating of “Buy” and a consensus target price of $32.67.

Maze Therapeutics Stock Down 6.0%

Shares of MAZE opened at $23.30 on Monday. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $25.50. The business has a 50-day simple moving average of $15.28 and a two-hundred day simple moving average of $12.28.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.02.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds have recently added to or reduced their stakes in MAZE. General Catalyst Group Management LLC bought a new stake in Maze Therapeutics during the first quarter worth about $11,405,000. Bessemer Group Inc. bought a new stake in Maze Therapeutics during the first quarter worth about $5,305,000. Bank of New York Mellon Corp bought a new stake in Maze Therapeutics during the first quarter worth about $190,000. New York State Common Retirement Fund bought a new stake in Maze Therapeutics during the first quarter worth about $25,000. Finally, Alphabet Inc. bought a new stake in Maze Therapeutics during the first quarter worth about $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.